ISR Articles

  1. Biologics Outsourcing Differences By Company Size 6/14/2022

    ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.

  2. De-Risking The Supply Chain 6/14/2022

    124 sponsors who outsource small molecule drug substance were asked what strategies they are currently using or plan to use to de-risk their supply chain —a particularly pertinent topic in light of the events over the past few years, ranging from the COVID-19 pandemic to the conflict in the Ukraine.

  3. Drug Innovators' Outlook On Innovative Treatments 6/14/2022

    134 outsourcers of biologic drug substance provided insight into their pipelines are impactingoutsourcing practices. Two-thirds (63%) said a focus on new, innovative treatments will impact outsourcing decisions.

  4. Unraveling Hybrid Clinical Trials: Challenges And Opportunities 6/10/2022

    Hybrid trials have undergone rapid evolution in the past few years. Examine this evolution, the reasons for confidence and concern, and how they may impact pharmaceutical development in the future.

  5. Outsourcing Highly Potent API – It's What You Know And Who You Know 6/2/2022

    Discover challenges for drug makers who may want to produce higher potency APIs but have built their manufacturing systems around broad-spectrum medications that don’t require high-containment facilities.

  6. How Service Providers Can Create Momentum In An Established Brand 5/27/2022

    To promote brand growth, companies must identify which brand components are succeeding and which may be falling short, as well as understand how these dynamics manifest in the larger organization’s successes and failures.

  7. Customer Loyalty In Small Molecule Drug Substance Manufacturing 5/4/2022

    ISR surveyed 124 sponsors who outsource small molecule drug product to gain insight into customer loyalty. Delve into the data of how the CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again.

  8. Outsourcers Are Feeling Uneasy About Continuity Of Supply 4/14/2022

    Find out how COVID-19 complications have picked up from the first year, with more outsourcers experiencing bigger obstacles when it comes to manufacturing, specifically with drug product.

  9. CDMO Preference For Small Molecule Drug Substance 4/13/2022

    ISR asked API outsourcers which CDMOs they are currently working with and which CDMO they prefer to use for all small molecule drug substance manufacturing. Delve into the data which showed that Cambrex, Patheon, Lonza, STA Pharma and Pfizer CentreOne are the preferred CDMOs among roughly one-third of their current customers.

  10. Preference Among Users: New And Emerging Biopharma 4/13/2022

    ISR asked new and emerging biopharma respondents which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer.